According to recent guidelines, people with moderate-to-severe CD are started on either Tumor Necrosis Factor alpha (TNF-α) inhibitor monotherapy, such as infliximab and adalimumab, or combined therapy consisting of TNF-α inhibitors and immunomodulators (thiopurines, 5-aminosalicylic acid (5-ASA), methotrexate) for the induction and maintenance of remission, with the use of corticosteroids for short-term management of flare-ups [16]. Here, TNF is linked to Cowden disease.